Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Arq 197
2. Arq-197
3. Arq197
1. 905854-02-6
2. Arq-197
3. Arq 197
4. (3r,4r)-3-(5,6-dihydro-4h-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1h-indol-3-yl)pyrrolidine-2,5-dione
5. Arq197
6. Pj4h73il17
7. Dtxsid60920316
8. (3r,4r)-3-(5,6-dihydro-4h-pyrrolo(3,2,1-ij)quinolin-1-yl)-4-(1h-indol-3-yl)pyrrolidine-2,5-dione
9. Tivantinibum
10. Refchem:898517
11. C-met Inhibitor Arq 197
12. Dtxcid301349230
13. (3r,4r)-3-(1-azatricyclo(6.3.1.0^(4,12))dodeca-2,4,6,8(12)-tetraen-3-yl)-4-(1h-indol-3-yl)pyrrolidine-2,5-dione
14. Tivantinib (arq 197)
15. 905853-99-8
16. Mfcd11977597
17. (rel)-tivantinib
18. Rel-(3r,4r)-3-(5,6-dihydro-4h-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1h-indol-3-yl)-2,5-pyrrolidinedione
19. 1000873-98-2
20. (3r,4r)-3-(1-azatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraen-3-yl)-4-(1h-indol-3-yl)pyrrolidine-2,5-dione
21. Tivantinib [inn]
22. Tivantinib [usan:inn]
23. Unii-pj4h73il17
24. Tivantinib; Arq197
25. Tivantinib [mi]
26. Tivantinib [jan]
27. Tivantinib [usan]
28. Arq 197 (tivantinib)
29. Tivantinib [who-dd]
30. Schembl44944
31. Orb322231
32. Tivantinib (jan/usan/inn)
33. Gtpl7948
34. Orb1301058
35. Orb1941247
36. Chembl2103882
37. Schembl29355700
38. Chebi:91398
39. Uceqxrcjxivodc-pmacekpbsa-n
40. Arq-197,tivantinib, Arq197
41. Arq197; Arq-197;tivantinib
42. Cs-m1640
43. Ex-a2169
44. Cas:905854-02-6;tivantinib
45. Bdbm50146168
46. Nsc758242
47. Nsc800951
48. S2753
49. Akos022182739
50. Ccg-268285
51. Db12200
52. Ebc-218037
53. Ft44530
54. Nsc-758242
55. Nsc-800951
56. Sdccgsbi-0654487.p001
57. (-)-trans-3-(5,6-dihydro-4h-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1h-indol-3-yl)pyrrolidine-2,5-dione
58. Ac-25009
59. Ac-35963
60. As-16991
61. Da-67145
62. Da-68209
63. Hy-50686
64. Hy-77493
65. Db-362059
66. Ns00073191
67. C77073
68. D10173
69. E82820
70. Brd-k33379087-001-01-8
71. Brd-k33379087-001-07-5
72. Q17123902
73. Z2242166213
74. (+/-)-trans-3-(5,6-dihydro-4h-pyrrolo[3,2,1-ij]quinolin-1-yl)-4(1h-indol-3-yl)pyrrolidine-2,5-dione
75. (+/-)-trans-3-(5,6-dihydro-4h-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1h-indol-3-yl) Pyrrolidine-2,5-dione
76. (+/-)-trans-3-(5,6-dihydro-4h-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1h-indol-3-yl)pyrrolidine-2,5-dione
77. (_)-trans-3-(5,6-dihydro-4h-pyrrolo[3,2,1-ij]quinolin-1-yl)-4(1h-indol-3-yl)pyrrolidine-2,5-dione
78. (3r,4r)-3-(2,3-dihydro-1h-pyrrolo[3,2,1-ij]quinolin-6-yl)-4-(1h-indol-3-yl)pyrrolidine-2,5-dione
79. (3r,4r)-3-(5,6-dihydro-4h-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1h-indol-3-yl)-pyrrolidine-2,5-dione
80. (3r,4r)-3-(5,6-dihydro-4h-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1h-indol-3-yl)pyrrolidine-2,5-dione; Arq 197;
81. 2,5-pyrrolidinedione, 3-(5,6-dihydro-4h-pyrrolo(3,2,1-ij)quinolin-1-yl)-4-(1h-indol-3-yl)-, (3r,4r)-
82. Tiv
83. Trans 3-(5,6-dihydro-4h-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1h-indol-3-yl)-pyrrolidine-2,5-dione
| Molecular Weight | 369.4 g/mol |
|---|---|
| Molecular Formula | C23H19N3O2 |
| XLogP3 | 2.9 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 2 |
| Exact Mass | Da |
| Monoisotopic Mass | Da |
| Topological Polar Surface Area | 66.9 |
| Heavy Atom Count | 28 |
| Formal Charge | 0 |
| Complexity | 666 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of hepatoblastoma
Tivantinib mediates its effects by inhibiting the activity of c-Met, a receptor tyrosine kinase that plays multiple key roles in human cancer, including cancer cell growth, survival, angiogenesis, invasion and metastasis. C-Met is abnormally activated in most cancers and is believed to control multiple signal transduction pathways involved in tumor growth and metastasis.
ABOUT THIS PAGE
85
PharmaCompass offers a list of Tivantinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Tivantinib manufacturer or Tivantinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Tivantinib manufacturer or Tivantinib supplier.
A Tivantinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tivantinib, including repackagers and relabelers. The FDA regulates Tivantinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tivantinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Tivantinib supplier is an individual or a company that provides Tivantinib active pharmaceutical ingredient (API) or Tivantinib finished formulations upon request. The Tivantinib suppliers may include Tivantinib API manufacturers, exporters, distributors and traders.
Tivantinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Tivantinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Tivantinib GMP manufacturer or Tivantinib GMP API supplier for your needs.
A Tivantinib CoA (Certificate of Analysis) is a formal document that attests to Tivantinib's compliance with Tivantinib specifications and serves as a tool for batch-level quality control.
Tivantinib CoA mostly includes findings from lab analyses of a specific batch. For each Tivantinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Tivantinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Tivantinib EP), Tivantinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tivantinib USP).
